Literature DB >> 10451694

Bone loss and glucocorticoid therapy in patients with respiratory disease.

A Fairney1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10451694      PMCID： PMC1765935          DOI： 10.1136/thx.54.2008.s52

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  37 in total

1.  Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  J E Compston; M Audran; B Avouac; G Bouvenot; J Devogelaer; R Eastell; F Fabris; C Gennari; E A Jones; J M Kaufman; E Lemmel; G Mazzuoli; D M Reid; J D Ringe; L Vanhaelst; R Ziegler; J Y Reginster
Journal:  Calcif Tissue Int       Date:  1996-11       Impact factor: 4.333

Review 2.  Inhaled glucocorticoids for asthma.

Authors:  P J Barnes
Journal:  N Engl J Med       Date:  1995-03-30       Impact factor: 91.245

3.  Glucocorticoid induced osteoporosis.

Authors:  C Gennari
Journal:  Clin Endocrinol (Oxf)       Date:  1994-09       Impact factor: 3.478

4.  The diagnosis of osteoporosis.

Authors:  J A Kanis; L J Melton; C Christiansen; C C Johnston; N Khaltaev
Journal:  J Bone Miner Res       Date:  1994-08       Impact factor: 6.741

5.  Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study.

Authors:  L J Walsh; C A Wong; M Pringle; A E Tattersfield
Journal:  BMJ       Date:  1996-08-10

6.  Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate.

Authors:  J Herrala; H Puolijoki; O Impivaara; K Liippo; E Tala; M M Nieminen
Journal:  Bone       Date:  1994 Nov-Dec       Impact factor: 4.398

7.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

8.  Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.

Authors:  P Garnero; W J Shih; E Gineyts; D B Karpf; P D Delmas
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

9.  Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.

Authors:  A Struys; A A Snelder; H Mulder
Journal:  Am J Med       Date:  1995-09       Impact factor: 4.965

10.  Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma.

Authors:  J H Toogood; J C Baskerville; A E Markov; A B Hodsman; L J Fraher; B Jennings; R G Haddad; D Drost
Journal:  J Allergy Clin Immunol       Date:  1995-08       Impact factor: 10.793
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.